Clinical efficacy of tolterodine for patients with overactive bladder after insufficient efficacy by monotherapy with alpha1-adrenoceptor antagonist
The efficacy of alpha1-adrenoceptor (alpha1-AR) antagonist and anticholinergic agent combined therapy for patients with benign prostatic hyperplasia (BPH) together with overactive bladder (OAB) has been controversial. The purpose of this study was to evaluate the effect of tolterodine combined with...
Saved in:
Published in | Nippon Hinyokika Gakkai zasshi Vol. 100; no. 7; p. 686 |
---|---|
Main Authors | , , , , , , , , , , , , |
Format | Journal Article |
Language | Japanese |
Published |
Japan
01.11.2009
|
Subjects | |
Online Access | Get more information |
Cover
Loading…
Abstract | The efficacy of alpha1-adrenoceptor (alpha1-AR) antagonist and anticholinergic agent combined therapy for patients with benign prostatic hyperplasia (BPH) together with overactive bladder (OAB) has been controversial. The purpose of this study was to evaluate the effect of tolterodine combined with alpha1-AR antagonist for patients with BPH and OAB after insufficient efficacy by monotherapy with alpha1-AR antagonist. The adverse event of this combined therapy was also assessed.
The study included 47 patients with BPH, whose OAB symptom persisted (OAB symptom score; OABSS > or =3) after monotherapy with alpha1-AR antagonist for more than 4 weeks. The mean age was 72.9 years and the mean prostate volume was 29.8 ml. Four mg/day of tolterodine with alpha-AR antagonist was administered for 8 weeks to patients. International prostate symptom score (IPSS), quality of life (QOL) index, OABSS, King's Health Questionnaire (KHQ) and residual urine volume (RUV) were assessed before and after combined therapy.
Six patients were dropped out from this study because of dry mouth, constipation, onset of other disease and insufficient efficacy by self-judgment. IPSS (from 15.1 +/- 6.8 to 11.0 +/- 7.9; P < 0.01), QOL index (from 4.3 +/- 1.1 to 3.6 +/- 1.3; P < 0.01) and OABSS (from 7.0 +/- 3.0 to 5.4 +/- 2.9; P < 0.01) of 41 patients improved significantly by combined therapy. The storage symptom of IPSS subscore improved significantly (from 8.0 +/- 2.9 to 6.5 +/- 2.8; P < 0.01), whereas the voiding symptom did not improve. Regarding KHQ, the score of 3 domains (impact on life, role limitation, and physical limitation) improved significantly (P < 0.05). RUV did not change and no serious adverse event including urinary retention was found in this study.
This study reveals that the combined therapy of alpha-AR antagonist and tolterodine represents an effective and safe treatment modality for patients with BPH and OAB, whose OAB symptom was not improved by antecedent monotherapy with alpha-AR antagonist. |
---|---|
AbstractList | The efficacy of alpha1-adrenoceptor (alpha1-AR) antagonist and anticholinergic agent combined therapy for patients with benign prostatic hyperplasia (BPH) together with overactive bladder (OAB) has been controversial. The purpose of this study was to evaluate the effect of tolterodine combined with alpha1-AR antagonist for patients with BPH and OAB after insufficient efficacy by monotherapy with alpha1-AR antagonist. The adverse event of this combined therapy was also assessed.
The study included 47 patients with BPH, whose OAB symptom persisted (OAB symptom score; OABSS > or =3) after monotherapy with alpha1-AR antagonist for more than 4 weeks. The mean age was 72.9 years and the mean prostate volume was 29.8 ml. Four mg/day of tolterodine with alpha-AR antagonist was administered for 8 weeks to patients. International prostate symptom score (IPSS), quality of life (QOL) index, OABSS, King's Health Questionnaire (KHQ) and residual urine volume (RUV) were assessed before and after combined therapy.
Six patients were dropped out from this study because of dry mouth, constipation, onset of other disease and insufficient efficacy by self-judgment. IPSS (from 15.1 +/- 6.8 to 11.0 +/- 7.9; P < 0.01), QOL index (from 4.3 +/- 1.1 to 3.6 +/- 1.3; P < 0.01) and OABSS (from 7.0 +/- 3.0 to 5.4 +/- 2.9; P < 0.01) of 41 patients improved significantly by combined therapy. The storage symptom of IPSS subscore improved significantly (from 8.0 +/- 2.9 to 6.5 +/- 2.8; P < 0.01), whereas the voiding symptom did not improve. Regarding KHQ, the score of 3 domains (impact on life, role limitation, and physical limitation) improved significantly (P < 0.05). RUV did not change and no serious adverse event including urinary retention was found in this study.
This study reveals that the combined therapy of alpha-AR antagonist and tolterodine represents an effective and safe treatment modality for patients with BPH and OAB, whose OAB symptom was not improved by antecedent monotherapy with alpha-AR antagonist. |
Author | Nakayama, Jiro Ueda, Tomohiro Okuyama, Akihiko Uchida, Kinya Takahashi, Toru Kojimaan, Yasuyuki Miyagawa, Yasushi Fukuhara, Shinichiro Kiuchi, Hiroshi Tsujimura, Akira Yamamoto, Keisuke Takao, Tetsuya Hirai, Toshiaki |
Author_xml | – sequence: 1 givenname: Akira surname: Tsujimura fullname: Tsujimura, Akira organization: Department of Urology, Osaka University Graduate School of Medicine – sequence: 2 givenname: Tetsuya surname: Takao fullname: Takao, Tetsuya – sequence: 3 givenname: Kinya surname: Uchida fullname: Uchida, Kinya – sequence: 4 givenname: Keisuke surname: Yamamoto fullname: Yamamoto, Keisuke – sequence: 5 givenname: Shinichiro surname: Fukuhara fullname: Fukuhara, Shinichiro – sequence: 6 givenname: Jiro surname: Nakayama fullname: Nakayama, Jiro – sequence: 7 givenname: Tomohiro surname: Ueda fullname: Ueda, Tomohiro – sequence: 8 givenname: Toshiaki surname: Hirai fullname: Hirai, Toshiaki – sequence: 9 givenname: Hiroshi surname: Kiuchi fullname: Kiuchi, Hiroshi – sequence: 10 givenname: Yasushi surname: Miyagawa fullname: Miyagawa, Yasushi – sequence: 11 givenname: Toru surname: Takahashi fullname: Takahashi, Toru – sequence: 12 givenname: Yasuyuki surname: Kojimaan fullname: Kojimaan, Yasuyuki – sequence: 13 givenname: Akihiko surname: Okuyama fullname: Okuyama, Akihiko |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/19999133$$D View this record in MEDLINE/PubMed |
BookMark | eNpFkM1OAjEUhbvACCJ7V6YvMNjb-e3SEBUTEjfsSae9lZLSTjoFM-_hAzsEjWdzNud-N-fckYkPHgl5ALYsRcOeDp0_nGJwS2BsWTXVhMwY45CVvKmnZNH3tmWMiYLxurglUxCjIM9n5HvlrLdKOorGjK4GGgxNwSWMQVuP1IRIO5ks-tTTL5v2NJwxSpXsGWnrpNYYqTRjnlrfny6US_af1w70GHxI-_GqG64I6bq9hEzqiD4o7NL4RPokP4O3fbonN0a6Hhe_Pifb15ftap1tPt7eV8-bTIkqz0RlTMFLLJkRsoAC2oZXQpdjT6iNEYqVAICMo9StwjpXIJgQXIgccg2Gz8njFdud2iPqXRftUcZh97cO_wE-KW0W |
ContentType | Journal Article |
DBID | CGR CUY CVF ECM EIF NPM |
DOI | 10.5980/jpnjurol.100.686 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | no_fulltext_linktorsrc |
ExternalDocumentID | 19999133 |
Genre | English Abstract Journal Article |
GroupedDBID | ALMA_UNASSIGNED_HOLDINGS CGR CUY CVF EBD ECM EIF EMOBN JSF KQ8 NPM OK1 RJT SV3 ZXP |
ID | FETCH-LOGICAL-c963-96ff425e50f9a4141b8269d500917ff9c05111e02eadbce73c19099299313d1f2 |
ISSN | 0021-5287 |
IngestDate | Thu May 23 23:53:13 EDT 2024 |
IsPeerReviewed | false |
IsScholarly | true |
Issue | 7 |
Language | Japanese |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c963-96ff425e50f9a4141b8269d500917ff9c05111e02eadbce73c19099299313d1f2 |
PMID | 19999133 |
ParticipantIDs | pubmed_primary_19999133 |
PublicationCentury | 2000 |
PublicationDate | 2009-Nov |
PublicationDateYYYYMMDD | 2009-11-01 |
PublicationDate_xml | – month: 11 year: 2009 text: 2009-Nov |
PublicationDecade | 2000 |
PublicationPlace | Japan |
PublicationPlace_xml | – name: Japan |
PublicationTitle | Nippon Hinyokika Gakkai zasshi |
PublicationTitleAlternate | Nihon Hinyokika Gakkai Zasshi |
PublicationYear | 2009 |
SSID | ssib000940274 ssib000412797 ssib000954699 ssib046627981 ssib002821952 ssib005153582 ssj0039373 ssib005879720 ssib008802122 |
Score | 1.8553222 |
Snippet | The efficacy of alpha1-adrenoceptor (alpha1-AR) antagonist and anticholinergic agent combined therapy for patients with benign prostatic hyperplasia (BPH)... |
SourceID | pubmed |
SourceType | Index Database |
StartPage | 686 |
SubjectTerms | Adrenergic alpha-1 Receptor Antagonists Adrenergic alpha-Antagonists - administration & dosage Adrenergic alpha-Antagonists - adverse effects Aged Aged, 80 and over Benzhydryl Compounds - administration & dosage Benzhydryl Compounds - adverse effects Cresols - administration & dosage Cresols - adverse effects Drug Therapy, Combination Humans Male Middle Aged Muscarinic Antagonists - administration & dosage Muscarinic Antagonists - adverse effects Phenylpropanolamine - administration & dosage Phenylpropanolamine - adverse effects Prostatic Hyperplasia - complications Quality of Life Tolterodine Tartrate Treatment Outcome Urinary Bladder, Overactive - drug therapy Urinary Bladder, Overactive - etiology |
Title | Clinical efficacy of tolterodine for patients with overactive bladder after insufficient efficacy by monotherapy with alpha1-adrenoceptor antagonist |
URI | https://www.ncbi.nlm.nih.gov/pubmed/19999133 |
Volume | 100 |
hasFullText | |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwELa6cOGCQLxf8oFblaXO20e0AiokespKy2nlOLE2zbaJ2ubQ_R38I_4YM7aTeKMFAZeotStL8Xwdj8fzfSbkvcTTL59Jzy-Z74VxzrxccuWpIslzGZQF0wp831bx8jz8ehFdzGY_naql7pCfyps7eSX_Y1VoA7siS_YfLDsMCg3wGewLT7AwPP_Kxmc9rbFEIQi8uB1P_Bs8AG8KDB-xhtAqp1oaG1ZsCu3j5vk1ep2dvSYci9K1nAQWBwzjQXAKb2NZWkfLhEN6LvMEcsAbrIrRdZh4urW1ZKI-2l1VbQvoWlbbY1NXtZh_EXUtqvkNROxX1ZA02HfratPtTIa3rnbDSpGJWuhUblYe9t1xaD-XV1VhuGww9ND8XWwEIK8xfKNq39XlraQGt-w-x1H7DPbIdi3uHfVi4SAycdxubOS0p8tBxHX95Lrdrrtdc40VIaeTn4JB242GB-oxcGZUOf7cOxHo7rtOyEmSopNduQmjkPmJe1DLQ0wEuBFuGPNbO2DGI1dBLUIu8_g9hdGcCB_cLwQfQ3-Iev48HaqcUO7QFFnY-TQn9TgxH6bTovVzzatM9lg61soekYd2k0Q_GsQ_JrO1eEJ-9GinPTppo6iDdgpopz3aKUKVjminFu1Uo526aB_Hy4_UQbsZ4g600xHtT0n2-VN2tvTsnSKehKXG47FSsEqV0UJxEbKQ5bC95kUEdmCJUlzChDNWLnxwsLksk0BCwMxhC8EDFhRM-c_IvW2zLV8QGkcFK_xEBkr5YQKuLVyoIE0LDouoH0f8JXlu5vCyNboxl_3svvptz2vyYPw3vCH3FTiq8i1EvYf8ncbVL46ZqKg |
link.rule.ids | 786 |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Clinical+efficacy+of+tolterodine+for+patients+with+overactive+bladder+after+insufficient+efficacy+by+monotherapy+with+alpha1-adrenoceptor+antagonist&rft.jtitle=Nippon+Hinyokika+Gakkai+zasshi&rft.au=Tsujimura%2C+Akira&rft.au=Takao%2C+Tetsuya&rft.au=Uchida%2C+Kinya&rft.au=Yamamoto%2C+Keisuke&rft.date=2009-11-01&rft.issn=0021-5287&rft.volume=100&rft.issue=7&rft.spage=686&rft_id=info:doi/10.5980%2Fjpnjurol.100.686&rft_id=info%3Apmid%2F19999133&rft_id=info%3Apmid%2F19999133&rft.externalDocID=19999133 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0021-5287&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0021-5287&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0021-5287&client=summon |